Related Experiment Video
Updated: Jul 14, 2025
06:00
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
234
The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis
Sarah Neu1, Rano Matta1, Jennifer A Locke1
1Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Urology
|October 7, 2023
Summary
Metformin use in older patients with type 2 diabetes was associated with a slightly higher rate of overactive bladder (OAB) medication use, suggesting no protective effect. This finding challenges the potential OAB benefits of metformin.
Area of Science:
- Gerontology
- Pharmacology
- Urology
Background:
- Metformin, a common diabetes medication, has shown potential in animal models to improve bladder overactivity.
- Overactive bladder (OAB) is a common condition affecting older adults, often managed with medication.
Purpose of the Study:
- To investigate the association between metformin use and the rate of overactive bladder (OAB) medication use in elderly patients with type 2 diabetes mellitus (DM2).
Main Methods:
- A retrospective nested case-control cohort study was conducted using large healthcare administrative databases.
- Patients with DM2 aged 69 years and older were included, with cases receiving OAB medication prescriptions matched to controls.
- Metformin prescription prior to OAB medication was assessed as the exposure, with adjusted odds ratios calculated.
Main Results:
- A cohort of 2,233,084 patients with DM2 was analyzed, identifying 16,549 cases and 64,171 controls.
- Metformin use showed a slight positive association with OAB medication use (aOR=1.07, 95% CI=1.03-1.12).
- This association persisted until cumulative metformin supply exceeded 2220 days, after which no significant association was found.
Conclusions:
- Metformin use in older patients with DM2 is associated with a slightly increased rate of OAB medication use.
- The findings do not support a protective role for metformin in preventing OAB in this population.
- No association was observed with prolonged metformin use (>2220 days).
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
215
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
215
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
188
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
188
01:30Urinary Tract Calculi III: Medical Management
9
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
9
01:17Oral Hypoglycemic Agents: Sulfonylureas
218
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
218
01:23Urinary Bladder
854
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
854
01:17Drugs for Treatment of Diarrhea-Predominant IBS
192
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
192